Why:
- Most of the profit is a Virginia allergy clinic, and its margin is probably rented. The child-therapy company being marketed earned ~64% of its FY2026 pre-tax profit from a three-clinic US allergy practice bought in June 2025 for USD 1.5 million (T1). The profit is real — the tax line proves it — but the practice's margin jumped from 1.9% to 12.9% in the first owned year, which outside benchmarks put at ~80% odds as a physician-pay transfer; half the uplift sits in unbooked retention options, and fully loaded the margin is nearer 7% (T2/T3). No public rationale for the deal exists anywhere.
- A quarter of revenue is billed to the promoter's own companies, largely unpaid. ₹20.9 crore of "export services" goes to the promoter's Singapore and US entities on a cost-plus contract whose markup is never disclosed; above a ~11% markup the India business is loss-making, and ₹11.3 crore of the billing — 62% of the whole receivable book — sat uncollected at 197 days (T1). The group's overseas operations are real (US Medicaid billing, an arm's-length LEGO Foundation grant), but the FY2026 billing increase maps almost exactly onto one year of that grant, which expires within two years of listing.
- The price assumes growth the like-for-like record does not show. On the filing's own pro forma, the comparable year is revenue +11.6% and profit DOWN 24.6%; children served are flat over two years while the centre count nearly doubled; and the band asks roughly 96 to 101 times earnings for it (T1/DERIVED). The largest single line in the use of proceeds is an unnamed acquisitions-and-general bucket at its 35% regulatory ceiling.
Valuation at the band
| Floor ₹227 (T1) | Cap ₹239 (T1) | |
|---|---|---|
| Bid window | 1 Sep to 3 Sep 2026 | |
| Post-issue shares (fully diluted) | 2,09,01,682 | 2,09,01,682 |
| Market capitalisation | ₹474 cr | ₹500 cr |
| P/E on FY2026 profit (post-issue shares) | 95.8x | 100.8x |
| Fresh issue | ₹119 cr | ₹125 cr |
| Promoter (via Singapore holdco) after | 68.77% | 68.77% |
The pre-IPO placements of May-June 2026 came in at ₹284-290 — 17-21% ABOVE this band — which is the honest counterpoint: the last cash investors paid more than the public is being asked to. The multiple is on a profit whose two largest components (the US margin and the promoter billing) are each at risk of reverting.
The story
You are buying India's largest child-neurodevelopment therapy network by centre count, packaged for listing with a small American allergy practice that produces most of the profit, a promoter-billed export line that produces most of the rest, and an expansion plan several times anything the company has ever executed.
What this business is
Mom's Belief runs 136-139 centres offering therapy for autistic and neurodivergent children — 9,205 children served in FY2026 at ~₹28,400 a year each — mostly as rooms and partnerships inside licensed professionals' clinics, plus school units and a nil-revenue training academy. Since June 2025 it also owns the Asthma & Allergy Center (Roanoke, Lynchburg and Salem, Virginia). FY2026 consolidated revenue ₹81.7 crore, profit ₹5.0 crore. The promoter's Singapore holding company also runs adjacent businesses (US diagnostics; an insurance-product brand from the same Gurugram building) outside the listed entity.
Easy or difficult business? Therapy delivery is real, needed and hard to standardise — and structurally open. Licensed professionals can compete five kilometres away after a 24-month gap, clinical attrition runs ~55%, there is no licensing regime protecting incumbents, and a funded competitor raised ₹65 crore nine days before this issue opened.
Key numbers
| ₹ cr | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Revenue | ~30.6 | ~36.4 | 81.7 |
| PAT | 0.9 | 5.9 | 5.0 |
| Operating cash flow | +2.1 | -1.8 | -1.9 |
FY2024-25 are India standalone; FY2026 consolidates the US practice from June 2025, so the growth is merger arithmetic (like-for-like: +11.6% revenue, -24.6% PAT). FY2025's profit was 94% a deferred-tax credit on ₹0.35 crore of pre-tax profit. Excluding the promoter-group receivable build, three-year operating cash is positive (~82% of profit) — the cash problem is the related-party collection, not the centres.
| FY2026 revenue by segment (T1 KPI table) | ₹ cr | Share |
|---|---|---|
| India therapy centres and related | 26.2 | 32.0% |
| Export of services (billed to promoter entities) | 20.9 | 25.6% |
| US allergy practice (from 23 Jun 2025) | 34.1 | 41.7% |
The segment profit split is disclosed only as what the notes themselves call "a balancing-figure illustration"; the US source entity's books are unaudited by the filing's own admission.
Scorecard
| Block | Rating | Why |
|---|---|---|
| Right to win | MARGINAL | Better than the raw KPIs suggest — every traceable centre cohort improved, four-year children served grew 33%, and the LEGO Foundation independently calls it the country's largest — but the barriers are thin, attrition is ~55%, the recent window is price-led on a flat cohort, and whether the India business makes money at all depends on an undisclosed related-party markup. |
| Industry and TAM | MARGINAL | Real, underserved category with ample share headroom (~0.5% of the sized pool) — but the sized pool covers only a third of revenue, the profit engine (US allergy) gets no market analysis at all, and the commissioned chapter carries AI-generated exhibits and a "7th globally" claim its own table cannot support. |
| Financial momentum | MARGINAL | The US profit is real and taxed but likely reverting toward ~7% fully loaded; the like-for-like year shrank profit 24.6%; the India margin gain from insourcing is genuine; every segment margin rests on a disclaimed plug. Middling, with the risk pointed down. |
| Risks, governance, RPTs | MARGINAL | Nil litigation against anyone, zero pledge, real arm's-length validators — against an audit-committee chair whose independence is contradicted by the filing's own pages, a lender that was simultaneously JV partner and vendor with the JV denied in the notes, a "For Profit Social Enterprise" expenditure test that only clears by counting US allergy costs as Indian child-welfare spending, and two SPA obligations missing from a Nil contingent-liability table. |
| Promoter and cap table | MARGINAL | The promoter put in ₹33.3 crore through the loss years (reconciled to the rupee), sells nothing, pledges nothing, and the last private money came in above the band. Against that: the listed entity's profitability is administered through the promoter's own entities at an undisclosed markup, ₹11.3 crore of it is uncollected, and the controlling stake sits in a Singapore holdco the Indian lock-in cannot reach inside. A markup at ~12%+ or continued non-collection would make this a FAIL. |
| Offer structure | MARGINAL | Clean shape — 100% fresh, no debt to repay, no proceeds to insiders, monitored — around mediocre objects: the largest line is an unnamed acquisitions/GCP bucket at its 35% ceiling, ₹24.6 crore pays rent on existing centres and ₹10.2 crore marketing while the promoter's entities owe the company 1.25x the India rent object, and the capex is budgeted at 2.4x the company's own realised fit-out cost. |
Watch out for
- The markup. The cost-plus percentage in the 2021 Carving Futures service agreement is the single number that decides whether the India business is profitable. It is not in 502 pages.
- Collection. Whether the ₹18.1 crore of promoter-group receivables (₹11.3 crore past 197 days) gets paid is the swing fact for both the cash story and the offer's honesty.
- The US compensation schedules. If the physicians' pay resets at the ~3-year option vesting, the profit engine has an expiry date inside everyone's forecast horizon.
- The LEGO expiry. The grant-funded work maps onto the export line's whole FY2026 increase and ends FY2027-28.
The offer
- Raising ₹119 to ₹125 crore at the band, all fresh issue, no offer for sale (T1).
- For ~32% growth capex (314-319 new centres and technology), ~28% rent and marketing on the existing estate, and an unnamed inorganic/general bucket up to the 35% ceiling (T1/DERIVED).
- Implied valuation ₹474 to ₹500 crore, from the table above.
- Promoters (via Carving Futures Pte. Ltd., Singapore) hold 91.72% before and 68.77% after, selling nothing (T1).
Assessed from the RHP with outside checks on the promoter group, the US acquisition and the India market. This filing pre-filed confidentially under SEBI's Reg 292E route in 2025; the RHP is its first public document. Numbers carry source tiers: (T1) the filing's audited/certified sections and exchange records, (T2) registries and filings of record, (T3) trade press and secondary sources, DERIVED where computed from cited inputs. Not a recommendation. The valuation section states what the announced band implies and is not a view on whether that price is right.